Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns a combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Final results from the CheckMate 067 study
Findings from the TiNivo-2 study
Evidence for efficacy is based on the results from the LAURA study
New indications concern treatment of locally advanced cervical cancer in combination with chemoradiotherapy and first-line treatment of advanced or recurrent endometrial carcinoma in combination with chemotherapy
Findings from the second interim analysis of the KEYNOTE-671 study
Findings from an updated analysis of the CIRCULATE-Japan GALAXY study
Evidence is based on the results from the IMscin001 study
Findings from the ENGOT-en11/GOG-3053/KEYNOTE-B21 study
It is intended for the treatment of adult patients with FRα-positive, platinum-resistant high grade serous epithelial ovarian, Fallopian tube, or primary peritoneal cancer
Primary results from the DESTINY-Breast12 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
